See Pharmaceutical Reviews Update – Issue 12 for important news and information regarding CADTH’s drug review programs. Highlights from this issue include:
A new process for the submission and review of cell and gene therapies
Updated guidelines on fees for CADTH pharmaceutical reviews
Pending…
A new project on Early Identification of Stroke is now available for feedback from all interested stakeholders.
Early Identification of Stroke
Call for Feedback: 2020-01-17Feedback Due By: 2020-01-31Consultation Document: Horizon Scanning ReportProduct Type: Issues in Emerging Health Technologies…
Read this month’s issue of New at CADTH. Here, you’ll find the latest information on our products and services, corporate news, and news flashes of upcoming events across Canada.
CADTH has received the following notice(s) of pending drug submission(s).
Brand name
Vonvendi
Generic name
von Willebrand Factor [recombinant]
Manufacturer
Shire Pharma Canada ULC, now part of Takeda
Indication(s)
von Willebrand disease, adults, treatment and perioperative management
Project Number…
Read this month’s issue of New at CADTH. Here, you’ll find the latest information on our products and services, corporate news, and news flashes of upcoming events across Canada.
A new project on Internet-Based Cognitive Behavioural Therapy for Post-Traumatic Stress Disorder is now available for feedback from all interested stakeholders.
Internet-Based Cognitive Behavioural Therapy for Post-Traumatic Stress Disorder
Call for Feedback: 2019-11-22Feedback Due By: 2019-12-…
Today, CADTH has issued final recommendations for:
lanadelumab (Takhzyro)
Indications: Hereditary angioedema, preventionRecommendation: Reimburse with clinical criteria and/or conditions
For more information
certolizumab pegol (Cimzia)
Indications: Psoriasis, moderate to severe…
Today, CADTH has issued final recommendations for:
teduglutide (Revestive)
Indications: Short Bowel Syndrome (SBS), pediatricsRecommendation: Reimburse with clinical criteria and/or conditions
For more information
Today, CADTH has issued recommendations for:
cyclosporine (Verkazia)
Indications : Severe vernal keratoconjunctivitis, pediatric (≥4 years)Recommendation : Reimburse with clinical criteria and/or conditions
For more information
Read this month’s issue of New at CADTH. Here, you’ll find the latest information on our products and services, corporate news, and news flashes of upcoming events across Canada.
Today, CADTH has issued final recommendations for:
onabotulinumtoxinA (Botox)
Indications: Migraine, chronicRecommendation: Reimburse with clinical criteria and/or conditions
For more information
Today, CADTH has issued final recommendations for:
Enasidenib (Idhifa) for Acute Myeloid Leukemia
Funding Request: For the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with an isocitrate dehydrogenase-2 (IDH2) mutationRecommendation: Do not…